NCT00751803

BI 44370 TA in Acute Migraine Attack

A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 416 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared to placebo and an active comparator.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	BI 44370 TA Low Dose
DRUG	Eletriptan
DRUG	Placebo
DRUG	BI 44370 TA Medium Dose

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-05-01
• First posted: 2008-09-12
• Last updated: 2014-11-24

Locations

52 sites across 9 countries: Belgium, El Salvador, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom